NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company focused on neurological disorders, has been added to the Russell Microcap Index effective June 29, 2026, as part of the annual Russell indexes reconstitution. The inclusion, announced by the company, places NeuroOne among the smallest publicly traded U.S. companies tracked by FTSE Russell, the global index provider.
The Russell Microcap Index comprises the 1,000 smallest securities in the Russell 2000 Index plus the next 1,000 smallest eligible securities by market capitalization. Membership in the broader Russell 3000 Index, which includes the 4,000 largest U.S. stocks by total market capitalization as of April 30, 2026, automatically qualifies companies for inclusion in growth and value style indexes. According to FTSE Russell, about $12.2 trillion in assets were benchmarked against Russell US indexes as of June 2025.
For NeuroOne, being added to the Russell Microcap Index may attract investment from index funds and institutional investors that track these benchmarks. This could increase trading liquidity and shareholder visibility. The company, headquartered in Eden Prairie, Minnesota, markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain, and OneRF Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations and surgical procedures while improving outcomes for patients with neurological disorders.
The reconstitution process is based on objective market-capitalization rankings and style attributes, as described on the FTSE Russell website. NeuroOne's inclusion reflects its market capitalization ranking as of the April 30 cutoff date. The company also engages in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
This index addition underscores NeuroOne's position in the medical technology sector, where it competes to transform surgical diagnosis and treatment. For investors and industry observers, the move signals the company's growth trajectory and potential for increased exposure among institutional portfolios. The impact of index membership can extend to broader market perception and access to capital, which are critical for a company focused on advancing neurological care.
